Wealth Alliance Sells 490 Shares of Glaukos Co. (NYSE:GKOS)

Wealth Alliance lowered its position in Glaukos Co. (NYSE:GKOS) by 23.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,606 shares of the medical instruments supplier’s stock after selling 490 shares during the quarter. Wealth Alliance’s holdings in Glaukos were worth $241,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of GKOS. Wellington Management Group LLP grew its position in shares of Glaukos by 294.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock worth $284,501,000 after buying an additional 1,630,270 shares in the last quarter. State Street Corp raised its holdings in shares of Glaukos by 5.3% in the third quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier’s stock valued at $254,626,000 after acquiring an additional 98,109 shares in the last quarter. Primecap Management Co. CA lifted its stake in Glaukos by 2.0% in the third quarter. Primecap Management Co. CA now owns 1,245,185 shares of the medical instruments supplier’s stock worth $162,223,000 after acquiring an additional 24,370 shares during the period. Geode Capital Management LLC grew its holdings in Glaukos by 6.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,172,016 shares of the medical instruments supplier’s stock worth $152,722,000 after acquiring an additional 66,134 shares in the last quarter. Finally, Loomis Sayles & Co. L P increased its position in Glaukos by 21.6% during the 3rd quarter. Loomis Sayles & Co. L P now owns 673,751 shares of the medical instruments supplier’s stock valued at $87,776,000 after purchasing an additional 119,527 shares during the period. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Price Performance

Shares of NYSE GKOS opened at $126.03 on Friday. Glaukos Co. has a fifty-two week low of $83.90 and a fifty-two week high of $163.71. The company has a market cap of $6.95 billion, a PE ratio of -43.91 and a beta of 1.04. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The business has a 50-day simple moving average of $152.75 and a two-hundred day simple moving average of $139.41.

Glaukos (NYSE:GKOS) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The company had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. As a group, equities analysts expect that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Insider Transactions at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 3,328 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. This trade represents a 3.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Gilbert H. Kliman sold 10,000 shares of Glaukos stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the sale, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,859,454.08. The trade was a 23.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,744 shares of company stock worth $2,792,151. Company insiders own 6.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on GKOS shares. Wells Fargo & Company upped their price target on shares of Glaukos from $153.00 to $160.00 and gave the stock an “overweight” rating in a research report on Friday. JPMorgan Chase & Co. upped their target price on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Citigroup upgraded Glaukos from a “neutral” rating to a “buy” rating and lifted their price target for the company from $132.00 to $162.00 in a report on Wednesday, December 11th. Stephens upgraded Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, BTIG Research lifted their target price on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $163.25.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.